Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting CD19 can work for patients with LBCL, but many relapse due to loss of CD19 expression
This Phase II trial explored a novel approach to target both CD19 and CD20 in LBCL treatment
More than 70% of patients had a complete response ...
Novel targeted therapy regimens show promise in aggressive AML subtype
MECOM-rearranged acute myeloid leukemia (AML) is an aggressive and hard-to-treat leukemia
Researchers combined three inhibitors...
ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers
Two clinical studies demonstrate high response rates by patients with two hard-to-treat and aggressive blood cancers
Pivekimab...
ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers characterized the microenvironment of a nodal T cell lymphoma that is difficult to diagnose and treat
The study identified CD40 as a potential biomarker associated with overall survival
Future studies may look at targeting the CD40 pathway as a potential therapeutic target
ORLANDO, DECEMBER 7, 2025 - Researchers at The University of Texas MD Anderson Cancer Center have characterized...
ASH 2025: Shorter azacitidine regimen safely improves outcomes in lower-risk MDS patients
Azacitidine is a type of targeted therapy known as a hypomethylating agent, commonly used in treating myelodysplastic syndromes (MDS)...
ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma
Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study
Durable...
ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers
New investigational therapy 77A is an antibody that converts a cancer survival protein (HSP70) into an immune system trigger
Targeting...
ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma
Anito-cel is an experimental CAR T cell therapy for relapsed/refractory multiple myeloma patients
In updated Phase II trial results...
Spatial analysis finds immune-rich pockets in diffuse large B-cell lymphoma tumors with clear treatment potential
Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL)
Immune-privileged DLBCLs...
Researchers identify genetic markers that affect treatment outcomes in patients with large B-cell lymphoma
Multiple genetic markers play a key role in the treatment outcomes of patients with large B-cell lymphoma (LBCL) who received chimeric antigen...
Stem cell transplant achieves positive outcomes in second remission for adolescents and young adults with ALL
A new study from The University of Texas MD Anderson Cancer Center and Dana-Farber Cancer Institute, published in American Journal of Hematology...
Patients receiving anti-cancer treatment near end of life experience higher rates of hospitalization, ED and ICU use, and less utilization of hospice
Patients who receive systemic anti-cancer treatment near end of life are more likely to be hospitalized, go to the intensive care unit or...